>

  • Showcases
  • >
  • EAN 2020 | Ocrelizumab benefits in MS extend to patients with previous treatment failure
Senior adult female with multiple sclerosis working around the home using various devices including technology to carry out everyday work

EAN 2020 | Ocrelizumab benefits in MS extend to patients with previous treatment failure

Bianca Weinstock-Guttman presents the 2-year CHORDS study findings showing good outcomes among patients with relapsing-remitting multiple sclerosis receiving ocrelizumab after a suboptimal response to previous disease-modifying therapy (3:17).

Don’t fall behind!

Get the latest headlines – in your specialties of choice – delivered straight to your inbox.

Showcase

MEET THE SENIOR TEAM

Lucy Piper

medwireNews Bureau Chief

Related Showcases

|